“These data add to the body of the evidence that the broad spectrum mechanism of action of a whole virus inactivated COVID-19 vaccine, like Covaxin is a viable option in this continuously evolving pandemic,” it said. Earlier on January 9, the company had said that trials indicated that its vaccine Covaxin is safe for booster dosage against COVID-19. The analysis showed that six months after a two-dose Covaxin (BBV152) vaccination series, cell-mediated immunity and neutralising antibodies to both homologous (D614G) and heterologous strains (Alpha, Beta, Delta, and Delta plus) persisted above baseline, although the magnitude of the responses had declined, the company said.
The Delta version was robustly neutralized by a booster dose of Covaxin, and the Omicron variant was neutralized in over 90% of blood samples. Covaxin (BBV152) booster dose has been demonstrated to neutralize both Omicron and Delta forms of COVID-19, according to Bharat Biotech. According to the business, a booster dosage of Covaxin resulted in robust neutralization of the Delta version and more than 90% of blood samples exhibited neutralization of the Omicron variation.
Suggestion For You:
Furthermore, neutralising antibodies against homologous and heterologous SARS-CoV-2 variants increased from 19 to 265 folds after a third vaccination, it added. Booster BBV152 vaccination is safe and may be necessary to ensure persistent immunity to prevent breakthrough infections, it added. “These trial results provide a strong foundation towards our goal to provide Covaxin as a booster dose. Our goal of developing a global vaccine against COVID-19 has been achieved with Covaxin indicated for adults, children, two-dose primary and booster doses. This enables the use of the vaccine as a universal vaccine,” Bharat Biotech Chairman and Managing Director Krishna Ella said.
Covaxin maker Bharat Biotech on Wednesday claimed that the booster shot of the Covid vaccine is capable of neutralizing both Omicron and Delta Variants of Covid-19, with over 90% of the test serum samples showing neutralization of Omicron. The Omicron variant, first reported from South Africa in late November last year, has triggered a fresh wave of infections worldwide. The study was conducted at the Emory Vaccine Centre in Atlanta (US) by Ocugen, a partner of the Indian vaccine maker as part of ongoing phase 2 clinical trials during which immune sera were analyzed from 13 trial participants, 28 days after their booster jabs. The participants had been administered the booster shots six months after their full vaccination with two primary doses.
For Latest News Follow us on Google News
- Show all
- Trending News
- Popular By week